Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3876
Aldeyra Therapeutics
ALDX
$70.6M
| $438K | ﹤0.01% |
84,471
+7,827
| +10% | +$40.2K |
2022 Q3
13 quarters
|
|
3877
PUT
Southern Company
SO
$96.3B
| $436K | ﹤0.01% |
5,000
| – | – |
2024 Q4
4 quarters
|
|
3878
Telkom Indonesia
TLK
$12.4B
| $436K | ﹤0.01% |
20,701
-9,532
| -32% | -$195K |
2025 Q3
1 quarter
|
|
3879
Inspired Entertainment
INSE
$91.2M
| $436K | ﹤0.01% |
46,535
+3,155
| +7% | +$26.6K |
2022 Q2
14 quarters
|
|
3880
Gencor Industries
GENC
$258M
| $435K | ﹤0.01% |
33,587
+1,610
| +5% | +$21.6K |
2023 Q4
8 quarters
|
|
|
CMRC
3881
Commerce.com Inc Series 1
CMRC
$269M
| $433K | ﹤0.01% |
105,082
+10,915
| +12% | +$50.3K |
2022 Q1
15 quarters
|
|
3882
Riverview Bancorp
RVSB
$120M
| $433K | ﹤0.01% |
86,231
+3,325
| +4% | +$17.4K |
2022 Q3
13 quarters
|
|
3883
Aclaris Therapeutics
ACRS
$646M
| $432K | ﹤0.01% |
143,414
+19,989
| +16% | +$50.5K |
2019 Q1
27 quarters
|
|
3884
Unusual Machines
UMAC
$1.12B
| $429K | ﹤0.01% |
33,650
+26,599
| +377% | +$312K |
2025 Q2
2 quarters
|
|
|
CIO
3885
DELISTED
City Office REIT
CIO
| $426K | ﹤0.01% |
60,887
+5,828
| +11% | +$40.3K |
2017 Q1
35 quarters
|
|
3886
First National Corp
FXNC
$272M
| $425K | ﹤0.01% |
16,825
+2,791
| +20% | +$66.3K |
2024 Q4
4 quarters
|
|
|
LOVE
3887
LoveSac
LOVE
$212M
| $421K | ﹤0.01% |
28,576
+1,999
| +8% | +$28.3K |
2018 Q3
29 quarters
|
|
3888
DiaMedica Therapeutics
DMAC
$444M
| $421K | ﹤0.01% |
52,911
+7,471
| +16% | +$55.9K |
2024 Q4
4 quarters
|
|
3889
Boston Omaha
BOC
$398M
| $420K | ﹤0.01% |
33,975
+3,279
| +11% | +$42.7K |
2023 Q4
8 quarters
|
|
3890
CALL
ING
ING
$99B
| $420K | ﹤0.01% |
+15,000
| New | +$387K |
2025 Q4
0 quarters
|
|
3891
Distribution Solutions Group
DSGR
$1.62B
| $420K | ﹤0.01% |
15,327
+1,201
| +9% | +$33.8K |
2016 Q3
37 quarters
|
|
3892
C4 Therapeutics
CCCC
$363M
| $419K | ﹤0.01% |
219,204
+176,142
| +409% | +$417K |
2022 Q1
15 quarters
|
|
|
WBTN
3893
WEBTOON Entertainment Inc
WBTN
$1.42B
| $418K | ﹤0.01% |
32,073
+6,804
| +27% | +$104K |
2024 Q2
6 quarters
|
|
3894
AB InBev
BUD
$145B
| $417K | ﹤0.01% |
6,518
-161,317
| -96% | -$10M |
2013 Q2
50 quarters
|
|
3895
RCI Hospitality Holdings
RICK
$203M
| $416K | ﹤0.01% |
17,462
+1,188
| +7% | +$30.4K |
2015 Q3
41 quarters
|
|
|
JCAP
3896
Jefferson Capital
JCAP
$1.11B
| $416K | ﹤0.01% |
18,624
-1,595
| -8% | -$32.2K |
2025 Q2
2 quarters
|
|
|
WOW
3897
DELISTED
WideOpenWest
WOW
| $415K | ﹤0.01% |
79,796
+8,606
| +12% | +$44.4K |
2017 Q2
34 quarters
|
|
3898
CALL
Constellation Brands
STZ
$19.3B
| $414K | ﹤0.01% |
+3,000
| New | +$412K |
2025 Q4
0 quarters
|
|
|
HUT
3899
PUT
Hut 8
HUT
$11B
| $413K | ﹤0.01% |
9,000
-414,700
| -98% | -$18.3M |
2025 Q3
1 quarter
|
|
3900
CALL
Infosys
INFY
$44.7B
| $413K | ﹤0.01% |
23,200
-2,669,500
| -99% | -$46.2M |
2025 Q3
1 quarter
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.